iRhythm Holdings, Inc. (IRTC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 10.13%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 10.13% | Share-based compensation / revenue. Period ending 2026-06-30. $83.64M ÷ $825.34M × 100 ≈ 10.13% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 825.34M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 83.64M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -24.87M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $825.34M | $83.64M | $-24.87M | (m) | (m) | 10.13% | (m) | (m) |
| 2026-03-31 | (m) | $787.85M | $86.43M | $-41.04M | (m) | (m) | 10.97% | (m) | (m) |
| 2025-12-31 | (m) | $747.14M | $88.28M | $-57.41M | (m) | (m) | 11.82% | (m) | (m) |
| 2025-09-30 | (m) | $702.57M | $83.19M | $-63.78M | (m) | (m) | 11.84% | (m) | (m) |
| 2025-06-30 | (m) | $657.23M | $79.34M | $-105.65M | (m) | (m) | 12.07% | (m) | (m) |
| 2025-03-31 | (m) | $618.59M | $78.33M | $-109.92M | (m) | (m) | 12.66% | (m) | (m) |
| 2024-12-31 | (m) | $591.84M | $75.98M | $-115.50M | (m) | (m) | 12.84% | (m) | (m) |
| 2024-09-30 | (m) | $560.02M | $83.82M | $-150.60M | (m) | (m) | 14.97% | (m) | (m) |
| 2024-06-30 | $68.41M | $537.09M | $87.67M | $-127.90M | (m) | 12.74% | 16.32% | (m) | (m) |
| 2024-03-31 | $62.40M | $513.17M | $79.94M | $-123.80M | $5.56M | 12.16% | 15.58% | -22.27× | Reported |
| 2023-12-31 | $60.24M | $492.68M | $77.20M | $-125.16M | $3.65M | 12.23% | 15.67% | -34.29× | Reported |
| 2023-09-30 | $57.50M | $472.79M | $69.15M | $-106.68M | $3.72M | 12.16% | 14.63% | -28.66× | Reported |
| 2023-06-30 | $52.64M | $452.06M | $61.09M | $-100.16M | $3.41M | 11.64% | 13.51% | -29.38× | Reported |
| 2023-03-31 | $50.91M | $429.98M | $62.09M | $-104.74M | $3.06M | 11.84% | 14.44% | -34.24× | Reported |
| 2022-12-31 | $46.61M | $410.92M | $57.74M | $-113.78M | $4.14M | 11.34% | 14.05% | -27.50× | Reported |
| 2022-09-30 | $45.80M | $380.11M | $53.82M | $-125.28M | $3.37M | 12.05% | 14.16% | -37.14× | Reported |
| 2022-06-30 | $43.04M | $361.67M | $53.04M | $-127.48M | $3.04M | 11.90% | 14.66% | -41.96× | Reported |
| 2022-03-31 | $40.70M | $340.89M | $48.20M | $-121.02M | $2.86M | 11.94% | 14.14% | -42.27× | Reported |
| 2021-12-31 | $38.67M | $322.82M | $54.53M | $-99.94M | $1.17M | 11.98% | 16.89% | -85.49× | Reported |
| 2021-09-30 | $38.41M | $319.83M | $56.65M | $-77.33M | $1.29M | 12.01% | 17.71% | -59.71× | Reported |
| 2021-06-30 | $38.49M | $306.34M | $61.93M | $-58.80M | $1.40M | 12.56% | 20.22% | -42.00× | Reported |
| 2021-03-31 | $41.42M | $275.94M | $61.44M | $-61.97M | $1.47M | 15.01% | 22.27% | -42.04× | Reported |
| 2020-12-31 | $41.33M | $265.17M | $41.52M | $-43.67M | $1.52M | 15.59% | 15.66% | -28.75× | Reported |
| 2020-09-30 | $38.99M | $245.46M | $34.69M | $-51.82M | $1.53M | 15.89% | 14.13% | -33.87× | Reported |
| 2020-06-30 | $43.72M | $228.19M | $24.65M | $-65.32M | $1.55M | 19.16% | 10.80% | -42.01× | Reported |
| 2020-03-31 | $39.02M | $229.75M | $21.69M | $-55.72M | $1.61M | 16.98% | 9.44% | -34.53× | Reported |
| 2019-12-31 | $37.30M | $214.55M | $26.24M | $-54.76M | $1.64M | 17.38% | 12.23% | -33.33× | Reported |
| 2019-09-30 | $35.12M | $197.23M | $23.86M | $-50.12M | $1.79M | 17.80% | 12.10% | -27.95× | Reported |
| 2019-06-30 | $27.56M | $181.80M | $20.75M | $-40.60M | $2.25M | 15.16% | 11.41% | -18.08× | Reported |
| 2019-03-31 | $23.49M | $163.94M | $17.50M | $-40.95M | $2.67M | 14.33% | 10.67% | -15.36× | Reported |
| 2018-12-31 | $20.75M | $147.29M | $16.33M | $-43.62M | $3.12M | 14.09% | 11.09% | -14.00× | Reported |
| 2018-09-30 | $17.89M | $132.32M | $14.63M | $-42.69M | $3.44M | 13.52% | 11.06% | -12.40× | Reported |
| 2018-06-30 | $16.52M | $119.25M | $13.15M | $-38.93M | $3.44M | 13.85% | 11.03% | -11.30× | Reported |
| 2018-03-31 | $14.73M | $107.64M | $11.34M | $-33.17M | $3.42M | 13.69% | 10.54% | -9.69× | Reported |
| 2017-12-31 | $13.34M | $98.51M | $10.12M | $-27.27M | $3.39M | 13.54% | 10.28% | -8.05× | Reported |
| 2017-09-30 | $11.49M | $89.03M | $7.64M | $-21.00M | $3.38M | 12.91% | 8.59% | -6.21× | Reported |
| 2017-06-30 | $9.34M | $80.78M | $5.31M | $-17.68M | $3.33M | 11.56% | 6.58% | -5.31× | Reported |
| 2017-03-31 | $8.23M | $72.66M | $3.49M | $-15.46M | $3.27M | 11.32% | 4.80% | -4.72× | Reported |
| 2016-12-31 | $7.15M | $64.07M | $1.87M | $-15.58M | $3.25M | 11.16% | 2.92% | -4.80× | Reported |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $48.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $41.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $6.35M | $36.14M | $1.41M | $-21.63M | $1.06M | 17.57% | 3.90% | -20.43× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $5.70M | $21.75M | $828.00K | $-14.77M | $774.00K | 26.20% | 3.81% | -19.08× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PULSE BIOSCIENCES, INC. (PLSE) | United States | $3.696B | -24.47 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 |